Search results for "androgens"

showing 10 items of 79 documents

Peripheral androgen blockade versus glandular androgen suppression in the treatment of hirsutism.

1991

Hirsutism in women is often explained on the basis of abnormal peripheral androgen metabolism. To determine whether serum markers of ovarian, adrenal, or peripheral androgen production may be helpful determinants in the treatment of hirsutism and to compare the efficacy of treatment with dexamethasone or spironolactone, 20 hyperandrogenic hirsute patients were treated for up to 2 years. Eleven women who were selected on the basis of sensitivity to dexamethasone were treated with a daily dose of 0.37 mg dexamethasone and had androgen levels suppressed into the normal range. Although significant (P less than .05), Ferriman-Gallwey scores decreased only by 20%: 14.2 +/- 0.5 to 11.4 +/- 0.6. Ni…

Adultmedicine.medical_specialtyHirsutismAdolescentmedicine.drug_classmedicine.medical_treatmentSpironolactoneAndrogen suppressionAntiandrogenAndrosteroneDexamethasonechemistry.chemical_compoundInternal medicinemedicineHumansTestosteronehirsutismDexamethasoneChemotherapybusiness.industryDehydroepiandrosterone SulfateAndrostenedioneObstetrics and GynecologyAndrogen AntagonistsDihydrotestosteroneGeneral MedicineDehydroepiandrosteroneAndrogenmedicine.diseaseAndrostane-317-diolDrug CombinationsEndocrinologychemistrySpironolactoneAndrogensCorticosteroidFemalebusinessmedicine.drugObstetrics and gynecology
researchProduct

Prevalence and metabolic characteristics of adrenal androgen excess in hyperandrogenic women with different phenotypes

2007

Background: Serum DHEAS has been found to be elevated in some women with polycystic ovary syndrome (PCOS). We wished to determine whether this prevalence is different in women with androgen excess who have different phenotypes and to correlate these findings with various cardiovascular and metabolic parameters. Methods: Two hundred and thirty-eight young hyperandrogenic women categorized into various diagnostic groups were evaluated for elevations in serum DHEAS, testosterone, glucose, insulin, quantitative insulin-sensitivity check index (QUICKI), cholesterol, HDL-C, LDL-C, triglycerides and C-reactive protein (CRP). Data were stratified based on elevations in DHEAS. Results: Serum DHEAS w…

Adultmedicine.medical_specialtyendocrine system diseasesEndocrinology Diabetes and Metabolismmedicine.medical_treatmentAndrogen Excesschemistry.chemical_compoundEndocrinologyInternal medicinePrevalenceHumansInsulinMedicineTestosteroneTestosteronebusiness.industryCholesterolInsulinPolycystic ovary syndrome (PCOS)Hyperandrogenismnutritional and metabolic diseasesmedicine.diseasePhenotypePolycystic ovaryPhenotypeEndocrinologychemistryAdrenal CortexAndrogensFemaleHyperandrogenismbusinessPolycystic Ovary SyndromeJournal of Endocrinological Investigation
researchProduct

Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guidelin…

2006

OBJECTIVE: The Androgen Excess Society (AES) charged a task force to review all available data and recommend an evidence-based definition for polycystic ovary syndrome (PCOS), whether already in use or not, to guide clinical diagnosis and future research. PARTICIPANTS: Participants included expert investigators in the field. EVIDENCE: Based on a systematic review of the published peer-reviewed medical literature, by querying MEDLINE databases, we tried to identify studies evaluating the epidemiology or phenotypic aspects of PCOS. CONSENSUS PROCESS: The task force drafted the initial report, following a consensus process via electronic communication, which was then reviewed and critiqued by …

ConsensusAndrogensHumansFemaleGuidelines as TopicHyperandrogenismSocieties Medicalpolycystic ovary syndrome cardiovascular risk insulin resistancePolycystic Ovary SyndromeThe Journal of clinical endocrinology and metabolism
researchProduct

Adjuncts for ovarian stimulation: when do we adopt “orphan indications” for approved drugs?

2009

Several drugs, shown to be safe for other uses, have proven to be highly effective adjuncts for ovarian stimulation. The authors evaluate these "orphan" indications and make recommendations so that more patients will benefit from their use.

Drugendocrine systemmedicine.medical_specialtyOrphan Drug ProductionResearch methodologymedia_common.quotation_subjectFertilization in VitroReproductive technologyAcide acétylsalicyliqueHealth servicesProstaglandin-Endoperoxide SynthaseOvulation InductionHumansMedicineIntensive care medicinemedia_commonGynecologyAspirinHuman Growth Hormonebusiness.industryObstetrics and GynecologyErgot DerivativesEstrogensMetforminReproductive MedicineDopamine AgonistsAndrogensFemaleFertility agentsLeuprolidebusinessContraceptives OralPolycystic Ovary SyndromeFertility and Sterility
researchProduct

Detection of a synthetic sex steroid in the American crocodile (Crocodylus acutus): Evidence for a novel environmental androgen

2017

Endocrine-disrupting contaminants (EDC's) are well known to alter sexual differentiation among vertebrates via estrogenic effects during development, particularly in organisms characterized by temperature-dependent sex determination. However, substances producing androgenic effects typically lack potency when tested in laboratory settings and are virtually unstudied in field settings. Here, we assay levels of a synthetic androgen, 17a-methyltestosterone (MT), in a heavily male-biased population of American crocodiles in the Tempisque River Basin of Costa Rica based on the recent hypothesis that this chemical is an EDC in developing crocodilian embryos. The presence of MT was documented in a…

Male0106 biological sciences0301 basic medicineHealth Toxicology and MutagenesisEndocrine DisruptorsCrocodile01 natural sciencesMethyltestosteroneGonadal Steroid HormonesAlligators and Crocodileseducation.field_of_studybiologyGeneral MedicinePollutionEnvironmental androgenAndrogensFemaleSteroidsEnvironmental MonitoringCosta Ricamedicine.medical_specialtyEnvironmental Engineeringfood.ingredient597.987 286 Crocodilia (Cocodrilos)medicine.drug_classPopulationCrocodylus acutusZoology010603 evolutionary biologyCrocodylus03 medical and health sciencesfoodRiversbiology.animalYolkInternal medicinemedicineAnimalsEnvironmental ChemistryeducationSexual differentiationPublic Health Environmental and Occupational HealthEstrogensGeneral ChemistryAndrogenbiology.organism_classificationUnited StatesCrocodylus030104 developmental biologyEndocrinologySex steroidWater Pollutants ChemicalEndocrine disrupting contaminantsChemosphere
researchProduct

Excretion and measurement of corticosterone and testosterone metabolites in bank voles (Myodes glareolus)

2017

The bank vole is a commonly used model species in behavioral and ecophysiological studies. Thus, presenting a validated method for noninvasive monitoring of corticosterone and testosterone secretion is of high relevance. Here, we evaluated the effect of time of day and an ACTH challenge test on measured fecal corticosterone (FCM) and testosterone (FTM) metabolites in both sexes. Furthermore, we performed radiometabolism experiments for both steroids and sexes to study metabolism and excretion of 3H-corticosterone and 3H-testosterone. FCM and FTM were analysed with a 5α-pregnane-3β,11β,21-triol-20-one enzyme immunoassay (EIA) and a testosterone (measuring 17β-hydroxyandrostanes) EIA, respect…

Male0106 biological sciences0301 basic medicinemedicine.medical_specialtymedicine.medical_treatmentUrineUrinalysisradiometabolism010603 evolutionary biology01 natural sciencesSteroidImmunoenzyme TechniquesExcretionFeces03 medical and health scienceschemistry.chemical_compoundstressEndocrinologyCorticosteroneInternal medicinemedicineAnimalsTestosteronebank voleta413TestosteroneFecesandrogeenitbiologyArvicolinaeandrogensMetabolismbiology.organism_classificationnon-invasive methodsBank voleACTH challenge030104 developmental biologyEndocrinologychemistryta1181FemaleAnimal Science and ZoologyCorticosterone
researchProduct

Radiotherapy before or during androgen-deprivation therapy does not blunt the exercise-induced body composition protective effects in prostate cancer…

2021

Background Androgen deprivation therapy (ADT) contributes to lean mass loss and adiposity increases in prostate cancer patients. Radiotherapy during ADT might act synergistically and further worsen body composition. Previous investigations have shown that resistance training is an effective method of preserving body composition during ADT, however, most have not accounted for direct or indirect effects of other therapies, such as radiotherapy. Therefore, the purpose of this study was to examine training adaptations of the tissue composition in patients receiving radiation therapy (RT) prior or during ADT. Methods Analyses were performed by combining data from two previous trials for a total…

Male0301 basic medicineAgingmedicine.medical_treatmentBiochemistryMuscle hypertrophylaw.inventionAndrogen deprivation therapyProstate cancer0302 clinical medicineEndocrinologyRandomized controlled triallawRandomized Controlled Trials as Topicadipositykuntoliikuntamuscle massAndrogensBody Compositionhypertrophyliikuntahoitomedicine.medical_specialtyUrology03 medical and health sciencesAtrophyatrophyGeneticsmedicineHumansAerobic exerciseMuscle StrengthMolecular BiologyatrofiaAgedkehonkoostumussyöpähoidotbusiness.industryProstatic NeoplasmsAndrogen AntagonistsCell Biologymedicine.diseaseRadiation therapysädehoito030104 developmental biologyresistance exerciselihasmassaLean body massbusinesslihassurkastumasairaudet030217 neurology & neurosurgery
researchProduct

The STAT3 Inhibitor Galiellalactone Reduces IL6-Mediated AR Activity in Benign and Malignant Prostate Models

2018

IL6/STAT3 signaling is associated with endocrine therapy resistance in prostate cancer, but therapies targeting this pathway in prostate cancer were unsuccessful in clinical trials so far. The mechanistic explanation for this phenomenon is currently unclear; however, IL6 has pleiotropic effects on a number of signaling pathways, including the androgen receptor (AR). Therefore, we investigated IL6-mediated AR activation in prostate cancer cell lines and ex vivo primary prostate tissue cultures in order to gain a better understanding on how to inhibit this process for future clinical trials. IL6 significantly increased androgen-dependent AR activity in LNCaP cells but importantly did not infl…

Male0301 basic medicineCancer ResearchINTERLEUKIN-6LactonesProstate cancerLIGAND-INDEPENDENT ACTIVATION0302 clinical medicineProstateDEPRIVATIONANDROGEN RECEPTORGLUCOCORTICOID-RECEPTORmedicine.anatomical_structureOncologyReceptors Androgen030220 oncology & carcinogenesisAndrogensSILTUXIMAB CNTO 328GROWTHSIGNAL TRANSDUCERSignal transductionLife Sciences & BiomedicineProtein BindingSignal TransductionSTAT3 Transcription FactorENZALUTAMIDEmedicine.drug_classMice NudeModels BiologicalTMPRSS203 medical and health sciencesProtein DomainsCell Line TumorLNCaPmedicineAnimalsHumansCastrationCANCER CELLSScience & TechnologyInterleukin-6business.industryProstatic NeoplasmsDNAmedicine.diseaseAndrogenXenograft Model Antitumor AssaysAndrogen receptor030104 developmental biologyCancer researchbusinessEx vivo
researchProduct

Aggressive variants of prostate cancer – Are we ready to apply specific treatment right now?

2019

Recently, adoption of novel drugs for systemic treatment of metastatic prostate cancer has led to a striking improvement of response rate and survival in both hormone-sensitive and castration-resistant disease. In most cases, prostate cancer essentially depends on androgen receptor signaling axis, even in castration-resistant setting, and hence may be targeted by second generation hormonal therapy. However, a subset of patients bears androgen-independent cancer biology with a short-term response to hormonal treatment, early and extensive visceral metastases, low PSA levels and poor outcomes. Identification and specific management of these rapidly fatal malignancies is of an unmet medical ne…

Male0301 basic medicineOncologymedicine.medical_specialtyAntineoplastic Agents HormonalDiseaseNeuroendocrine differentiationSmall-cell carcinoma03 medical and health sciencesProstate cancer0302 clinical medicineInternal medicineBiomarkers TumormedicineHumansRadiology Nuclear Medicine and imagingResponse rate (survey)business.industryGeneral Medicinemedicine.diseaseAndrogen receptorProstatic Neoplasms Castration-Resistant030104 developmental biologyOncologyReceptors Androgen030220 oncology & carcinogenesisAndrogensAdenocarcinomaHormonal therapybusinessCancer Treatment Reviews
researchProduct

Aromatase Inhibitors Plus Weight Loss Improves the Hormonal Profile of Obese Hypogonadal Men Without Causing Major Side Effects

2020

Objective: In obese men, the increased expression of the aromatase enzyme in adipose tissue leads to high conversion of androgens to estrogens contributing to hypogonadotropic hypogonadism (HHG). Our objective is to evaluate efficacy and safety of weight loss (WL) plus aromatase inhibitor (AI) therapy in severely obese men with HHG. We hypothesize that AI+WL will be more effective as compared to WL alone in improving the hormonal profile, thus muscle strength and symptoms of HHG (primary outcomes), with no significant adverse effects on lean mass, metabolic profile, and bone mineral density (secondary outcomes).Design: Randomized double-blind placebo-controlled pilot trial.Methods: Twenty-t…

Male0301 basic medicineobesityBone densityEndocrinology Diabetes and MetabolismPilot Projectslcsh:Diseases of the endocrine glands. Clinical endocrinologyaromatase inhibitorsEndocrinology0302 clinical medicineBone DensityWeight lossMedicineTestosteroneTestosteroneBone mineralEstradiolMiddle AgedPrognosisClinical TrialAndrogensMetabolomemedicine.symptombone microarchitecturemedicine.drugAdultmedicine.medical_specialtyHormone Replacement Therapymedicine.drug_classAnastrozole030209 endocrinology & metabolismsex hormonesBone and Bones03 medical and health sciencesDouble-Blind MethodHypogonadotropic hypogonadismInternal medicineWeight LossHumanshypogonadismMuscle StrengthAgedbody compositionlcsh:RC648-665Aromatase inhibitorbusiness.industrymedicine.disease030104 developmental biologyEndocrinologyLean body massbusinessBiomarkersFollow-Up StudiesFrontiers in Endocrinology
researchProduct